These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 25679409

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies.
    Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E.
    J Natl Cancer Inst; 2005 Nov 16; 97(22):1663-70. PubMed ID: 16288119
    [Abstract] [Full Text] [Related]

  • 23. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF, Sutton VR, Li W, Burgess J, McKEnzie IF, Pietersz GA, Trapani JA.
    Cancer Res; 1994 Dec 01; 54(23):6160-6. PubMed ID: 7954462
    [Abstract] [Full Text] [Related]

  • 24. Modulating antibody-dependent cellular cytotoxicity of epidermal growth factor receptor-specific heavy-chain antibodies through hinge engineering.
    D'Eall C, Pon RA, Rossotti MA, Krahn N, Spearman M, Callaghan D, van Faassen H, Hussack G, Stetefeld J, Butler M, Durocher Y, Zhang J, Henry KA, Tanha J.
    Immunol Cell Biol; 2019 Jul 01; 97(6):526-537. PubMed ID: 30680791
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
    Gerdes CA, Nicolini VG, Herter S, van Puijenbroek E, Lang S, Roemmele M, Moessner E, Freytag O, Friess T, Ries CH, Bossenmaier B, Mueller HJ, Umaña P.
    Clin Cancer Res; 2013 Mar 01; 19(5):1126-38. PubMed ID: 23209031
    [Abstract] [Full Text] [Related]

  • 30. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
    Ciardiello F, Bianco R, Damiano V, De Lorenzo S, Pepe S, De Placido S, Fan Z, Mendelsohn J, Bianco AR, Tortora G.
    Clin Cancer Res; 1999 Apr 15; 5(4):909-16. PubMed ID: 10213228
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
    Khelwatty SA, Essapen S, Seddon AM, Fan Z, Modjtahedi H.
    Br J Cancer; 2015 Sep 29; 113(7):1010-9. PubMed ID: 26372697
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. In vitro and in vivo antitumor effects of recombinant bispecific antibodies based on humanized anti-EGFR antibody.
    Watanabe Y, Asano R, Arai K, Shimomura I, Ogata H, Kawaguchi H, Hayashi H, Ohtsuka H, Yoshida H, Katayose Y, Egawa S, Nakanishi T, Umetsu M, Yasui H, Ishida T, Imai K, Kudo T, Unno M, Kumagai I.
    Oncol Rep; 2011 Oct 29; 26(4):949-55. PubMed ID: 21743971
    [Abstract] [Full Text] [Related]

  • 40. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
    Prewett MC, Hooper AT, Bassi R, Ellis LM, Waksal HW, Hicklin DJ.
    Clin Cancer Res; 2002 May 29; 8(5):994-1003. PubMed ID: 12006511
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.